EU mulls new Prevnar 13 indication

Share this article:

The EU is mulling an expanded indication for Pfizer's pneumococcal vaccine Prevnar 13. PM Live reports that expanding the use to include prevention of community-acquired pneumonia among the elderly could mean an additional $1 billion in sales. The drug is already approved for preventing invasive pneumococcal diseases among adults.

The US is set to consider an expanded indication in September, and the US Advisory Committee on Immunization Practices is expected to weigh in sometime this month.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.